Fulgent Genetics Operating Income Over Time
| FLGT Stock | USD 23.36 0.36 1.57% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Fulgent Genetics Performance and Fulgent Genetics Correlation. Is there potential for Health Care Providers & Services market expansion? Will Fulgent introduce new products? Factors like these will boost the valuation of Fulgent Genetics. Market participants price Fulgent higher when confident in its future expansion prospects. Understanding fair value requires weighing current performance against future potential. All the valuation information about Fulgent Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.99) | Earnings Share (1.40) | Revenue Per Share | Quarterly Revenue Growth 0.172 | Return On Assets |
Investors evaluate Fulgent Genetics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Fulgent Genetics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause Fulgent Genetics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Fulgent Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulgent Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Fulgent Genetics' market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Operating Income Analysis
Compare Fulgent Genetics and related stocks such as Myriad Genetics, Personalis, and DarioHealth Corp Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MYGN | (8.9 M) | 157.8 M | 180.3 M | 228 M | 274.4 M | 134.2 M | 166.8 M | 49.4 M | 118.7 M | 7.6 M | (194.8 M) | (190.5 M) | (140.6 M) | (257.4 M) | (123.5 M) | (111.2 M) | (105.6 M) |
| PSNL | (22.2 M) | (22.2 M) | (22.2 M) | (22.2 M) | (22.2 M) | (22.2 M) | (22.2 M) | (22.2 M) | (13.8 M) | (22.4 M) | (42.1 M) | (65.4 M) | (115.5 M) | (109.9 M) | (68.3 M) | (61.4 M) | (64.5 M) |
| DRIO | (4 M) | (4 M) | (4 M) | (13.6 M) | (11.4 M) | (7.7 M) | (11.1 M) | (14.4 M) | (17.7 M) | (17.7 M) | (29.9 M) | (76.5 M) | (56.8 M) | (56.2 M) | (57.7 M) | (52 M) | (49.4 M) |
| CSTL | (10.9 M) | (10.9 M) | (10.9 M) | (10.9 M) | (10.9 M) | (10.9 M) | (10.9 M) | (10.9 M) | (3.8 M) | 7.3 M | (6.5 M) | (40.1 M) | (72.9 M) | (68 M) | 8.7 M | 7.8 M | 8.2 M |
| CDNA | (2.3 M) | (2.3 M) | (2.3 M) | (857 K) | 1.2 M | (11.9 M) | (37.3 M) | (20.3 M) | (15.6 M) | (24.5 M) | (22.5 M) | (29.7 M) | (77.2 M) | (203.4 M) | 40.8 M | 36.7 M | 38.5 M |
| BFLY | (53.1 M) | (53.1 M) | (53.1 M) | (53.1 M) | (53.1 M) | (53.1 M) | (53.1 M) | (53.1 M) | (53.1 M) | (102.3 M) | (161.6 M) | (192.7 M) | (193 M) | (145.6 M) | (74.4 M) | (67 M) | (70.3 M) |
| ARVN | (16.5 M) | (16.5 M) | (16.5 M) | (16.5 M) | (16.5 M) | (16.5 M) | (16.5 M) | (24.8 M) | (43.8 M) | (51.5 M) | (124.9 M) | (195.3 M) | (263.2 M) | (401.5 M) | (250.2 M) | (225.2 M) | (236.4 M) |
| VALN | (1.4 M) | (4.5 M) | (12.8 M) | (20.9 M) | (23.8 M) | (19.9 M) | (42.6 M) | (4 M) | 6.3 M | (811 K) | (55.1 M) | (61.4 M) | (113.4 M) | (82.1 M) | 13.3 M | 12 M | 12.6 M |
| AVXL | (14.5 K) | (4.3 M) | (2.1 M) | (3 M) | (7.1 M) | (15.6 M) | (15.5 M) | (19.2 M) | (28.8 M) | (31.1 M) | (41.9 M) | (51 M) | (47.5 M) | (52.9 M) | (51.4 M) | (46.3 M) | (44 M) |
| PACB | (23.4 M) | (109.8 M) | (94.3 M) | (77.5 M) | (62.9 M) | (29.1 M) | (71.2 M) | (89.8 M) | (101 M) | (100.5 M) | (104.4 M) | (210.4 M) | (307.2 M) | (334.5 M) | (474.3 M) | (426.9 M) | (405.5 M) |
Fulgent Genetics and related stocks such as Myriad Genetics, Personalis, and DarioHealth Corp Operating Income description
Operating Income is the amount of profit realized from Fulgent Genetics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Fulgent Genetics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Fulgent Genetics | FLGT |
Specialization | Health Care, Health Care Equipment & Services |
| Business Address | 4399 Santa Anita |
| Exchange | NASDAQ Exchange |
USD 23.36
Additional Tools for Fulgent Stock Analysis
When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.